Denali Therapeutics Inc. $DNLI Shares Bought by Aberdeen Group plc

Aberdeen Group plc grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 902,751 shares of the company’s stock after acquiring an additional 142,936 shares during the period. Aberdeen Group plc owned about 0.62% of Denali Therapeutics worth $12,629,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 15.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after buying an additional 753 shares during the period. Knights of Columbus Asset Advisors LLC increased its stake in shares of Denali Therapeutics by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock worth $548,000 after acquiring an additional 1,058 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after acquiring an additional 1,551 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after acquiring an additional 2,052 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Denali Therapeutics by 20.7% in the first quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company’s stock worth $164,000 after acquiring an additional 2,072 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Trading Up 7.2%

Denali Therapeutics stock opened at $16.31 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -5.82 and a beta of 1.30. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company’s fifty day moving average price is $14.67 and its two-hundred day moving average price is $14.27.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the company earned ($0.59) EPS. On average, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,937 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carole Ho sold 2,937 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider owned 217,391 shares of the company’s stock, valued at $2,952,169.78. This trade represents a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,680 shares of company stock valued at $91,569 over the last 90 days. Corporate insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DNLI shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Finally, Morgan Stanley lowered their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $33.50.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.